Skip to main content
Rebecca Wates on Muck Rack

Rebecca Wates

As seen in: Biocompare
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rebecca

Contact Rebecca, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Therapeutic mAb Engineering Considerations

|
By Bethany Cragoe, Rebecca Wates, Michael Scott Long
| Biocompare Verified
Monoclonal antibodies (mAbs) are classic examples of personalized diagnostics and therapeutics (Malik and Ghatol, 2021). They bind specifically to nearly any therapeutically pertinent biomolecule and can be produced by a wide range of engineered organisms (Eidenberger et al., 2023). A common use of mAbs is to help the immune system target cancer (Zinn et al., 2023) and inflammatory disease (Zhu et al., 2023), such as for past emergency use against SARS-CoV-2 (Ravi et al., 2023).
Open in Who Shared Issue with article?
See all 1 articles